Compare Novo Nordisk A/S (NVO) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PAGSEG Inc — how do they compare? Novo Nordisk A/S trades at $38.52 (market cap $165.31B), while PAGSEG Inc trades at $11.05 (market cap $2.94B). The key difference: Novo Nordisk A/S is far larger — about 56.2× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.49%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and PAGSEG Inc for 26 Days on average.
| NVO | PAGS | |
|---|---|---|
Market Cap | $165.31B | $2.94B |
Volume | 11,432,838 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $63.98 | $12.00 |
52-Week Low | $35.29 | $8.44 |
Typical Hold Time | 116 Days | 26 Days |
Enterprise Value | $179.56B | $11.02B |
Dividend Yield | 4.71% | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
PAGS trades at $10.81, up 2.81% today, with a bullish technical signal from moving averages. The stock shows strong valuation metrics with a P/E of 7.1 and P/S of 0.74, supported by a 10.45% net income margin and recent earnings beats. A dividend of $0.28 is scheduled for September 2026, enhancing income appeal. Revenue growth remains steady, with 2026 guidance maintained despite a challenging macro environment.
Outlook is positive with analyst consensus at Buy (62.5%) and a $10.70 price target, though risks include elevated credit losses and Brazilian interest rate volatility. The stock's low valuation and dividend yield present a value opportunity, but investors must monitor execution on credit quality and banking growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
